Bristol Myers Squibb (BMY) Cash from Investing Activities (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash from Investing Activities for 18 consecutive years, with -$1.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 241.23% year-over-year to -$1.6 billion in Q2 2026; TTM through Jun 2026 was -$4.9 billion, a 253.64% decrease from a year earlier, with the FY2025 full-year figure at -$4.1 billion, up 80.65% from the prior year.
• Cash from Investing Activities was -$1.6 billion for Q2 2026 at Bristol Myers Squibb, down from -$131.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.2 billion in Q4 2022 and troughed at -$19.6 billion in Q1 2024.
• A 5-year average of -$1.7 billion and a median of -$441.5 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 202.49% in 2022 and tumbled 9241.9% in 2024, its largest moves.
• Over 5 years, Cash from Investing Activities stood at $1.2 billion in 2022, then plunged by 210.96% to -$1.3 billion in 2023, then soared by 85.44% to -$196.0 million in 2024, then tumbled by 643.88% to -$1.5 billion in 2025, then declined by 10.7% to -$1.6 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$1.6 billion (Q2 2026), -$131.0 million (Q1 2026), and -$1.5 billion (Q4 2025), per Business Quant data.